Meredith Faggen
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Meredith Faggen
Jul 29, 2024, 11:19 |
Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 25, 2024, 20:48 |
Insight
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Dana-Farber’s Breast Oncology Center shared on X: "New in JCO Oncology Practice: Subcutaneous vs Intravenous…
Jul 20, 2024, 11:01 |
Insight
Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial
Paolo Tarantino shared a post on LinkedIn about a paper titled "Adjuvant Trastuzumab Emtansine Versus…
Jul 5, 2024, 06:54 |
Blog
Paolo Tarantino: Nearly 1000 downloads in less than a week for our ATEMPT 5-year publication
Paolo Tarantino, posted on X: "Nearly 1000 downloads in less than a week for our…
Jul 1, 2024, 15:23 |
Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
All:
5
Posts:
1 - 100
ASTRO24: 15 Posts Not To Miss From Day 4
Top 100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2024
Paper Alert! Cutaneous Metastases in Thyroid Cancer: A Comprehensive Review of 136 Cases
ASTRO 24: 15 Posts Not to Miss From Day 3
Gavin Creel: Broadway Icon Dies After Battle with Rare Sarcoma at 48
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube